In a report released today, Marie Thibault from BTIG maintained a Buy rating on Venus Concept (VERO – Research Report), with a price target of $1.00. The company’s shares closed yesterday at $0.37.
Thibault covers the Healthcare sector, focusing on stocks such as Masimo, Boston Scientific, and Edwards Lifesciences. According to TipRanks, Thibault has an average return of 8.7% and a 40.21% success rate on recommended stocks.
Currently, the analyst consensus on Venus Concept is a Moderate Buy with an average price target of $0.88.
See today’s best-performing stocks on TipRanks >>
Based on Venus Concept’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $21.54 million and a GAAP net loss of $14.61 million. In comparison, last year the company earned a revenue of $24.56 million and had a GAAP net loss of $9.8 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Venus Concept, Inc. is a medical aesthetic technology company. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded in 2002 and is headquartered in Toronto, Canada.
Read More on VERO:
- Venus Concept Announces Strategic Business Realignment to Accelerate Its Path to Long-Term, Sustainable, Profitability and Reports Preliminary Revenue Results for Fourth Quarter and Fiscal Year 2022
- Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
- Venus Concept receives FDA 510k clearance to market AI.ME technology
